As presented at the 2026 ASCO Genitourinary Cancers Symposium, in the phase 2 INDIBLADE trial, induction therapy with ipilimumab and nivolumab followed by consolidating chemoradiotherapy in stage II/III muscle-invasive bladder cancer led to encouraging bladder-intact event-free survival outcomes that were associated with ctDNA clearance.
- Jan-Jaap J. Mellema
- Chantal F. Stockem
- Michiel S. van der Heijden
